Filing Details

Accession Number:
0000947871-20-000981
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-30 16:44:13
Reporting Period:
2020-12-28
Accepted Time:
2020-12-30 16:44:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1626199 Alpine Immune Sciences Inc. ALPN () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No Yes No
1682115 Orbimed Capital Gp Vi Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-12-28 600,000 $14.25 3,070,955 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Footnotes
  1. These shares of the Issuer's common stock ("Shares") were sold in a block order at a price of $14.25.
  2. The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VI. OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
  3. This report on Form 4 is filed by OrbiMed Advisors and OrbiMed GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter A. Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or Peter A. Thompson, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.